Itonic Holdings Ltd. (NASDAQ:ITOC) Shares Shorted: Short Interest Down 59.8% in October

Itonic Holdings Ltd. (NASDAQ:ITOC – Get Free Report) was the target of a large decline in short interest in October. As of October 30th, there was short interest totaling 4,034 shares, a decline of 59.8% from the October 15th total of 10,047 shares. Based on an average daily volume of 19,180 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Itonic from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the company currently has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on Itonic

Itonic Price Performance

Itonic stock traded down $0.10 during mid-day trading on Monday, reaching $1.89. 47,646 shares of the company were exchanged, compared to its average volume of 29,414. The company has a fifty day simple moving average of $3.64 and a 200-day simple moving average of $4.74. Itonic has a 12 month low of $1.63 and a 12 month high of $18.40.

Itonic (NASDAQ:ITOC – Get Free Report) last released its earnings results on Wednesday, September 30th. The company reported ($0.75) earnings per share for the quarter. The firm had revenue of $0.05 million during the quarter.

About Itonic

(Get Free Report)

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.

Further Reading

Receive News & Ratings for Itonic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Itonic and related companies with MarketBeat.com's FREE daily email newsletter.